Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE.

ABSTRACT:

Objective

Anifrolumab is a fully human immunoglobulin G₁ κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe SLE, anifrolumab treatment demonstrated substantial reductions in multiple clinical endpoints. Here, we evaluated serum proteins and immune cells associated with SLE pathogenesis, type I interferon gene signature (IFNGS) test status and disease activity, and how anifrolumab affected these components.

Methods

Whole blood samples were collected from patients enrolled in MUSE (NCT01438489) for serum protein and cellular assessments at baseline and subsequent time points. Data were parsed by IFNGS test status (high/low) and disease activity. Protein expression and immune

SUBMITTER: Casey KA 

PROVIDER: S-EPMC6257383 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature